Ongkingco J R, Ruley E J, Turner M E, Fragale M R
Department of Pediatric Nephrology, Children's National Medical Center, George Washington University School of Medicine, Washington, D.C.
Am J Nephrol. 1994;14(1):14-8. doi: 10.1159/000168680.
The subcutaneous administration of recombinant human erythropoietin is effective in the treatment of anemia of end-stage renal disease. Single-dose pharmacokinetic studies suggest the possibility of less frequent dosing via the subcutaneous route. In this study, dosing once-weekly was as effective as thrice-weekly subcutaneous dosing in maintaining the corrected hematocrit in a group of children receiving continuous cycling peritoneal dialysis. This regimen was preferred by and beneficial to both patients and their parents.
